DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Drug Discrimination in Methadone-Maintained Humans Study 1

Information source: University of Arkansas
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Drug Dependence

Intervention: Cycloserine (Drug); Diltiazem (Drug); Gabapentin (Drug); Isradipine (Drug); Naloxone (Drug); Nifedipine (Drug); Placebo (Drug); Saline (Device); Verapamil (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: University of Arkansas

Official(s) and/or principal investigator(s):
Alison Oliveto, PhD, Principal Investigator, Affiliation: University of Arkansas


This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e. g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.

Clinical Details

Official title: Drug Discrimination in Methadone-Maintained Humans Study 1

Study design: Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)

Primary outcome: Drug Discrimination Measure

Secondary outcome:

Self-reported effects

Vital Signs


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria: 1. Must be between the ages of 18-65. 2. Participation in the UAMS Substance Abuse Treatment Clinic Methadone Maintenance Program or the CATAR Clinic Little Rock with maintenance on a stable dose of

methadone (+ or - 10 mg) for at least 1 month prior to study entry.

3. Subjects would have to be in "good standing" in the methadone maintenance program in order to participate; i. e., compliance with scheduled medication and group therapy session hours. This would be defined as < 3 missed methadone medications and missed < 3 group or <3 individual therapy sessions in the two months prior to study participation 4. Subjects must submit a urine sample negative for illicit drugs prior to study entry. 5. Subjects must be able to read and understand English. Exclusion Criteria: Exclusion criteria 1. Ill health (major cardiovascular, renal, endocrine, hepatic disorder, to be determined by history provided by the prospective subject or laboratory evaluation as outlined below). 2. Current diagnosis of other drug or alcohol physical dependence (other than tobacco). 3. History of major psychiatric disorder (psychosis, schizophrenia, bipolar, depression) 4. Pregnancy, plans to become pregnant or inadequate birth control. 5. Present or recent use of over-the-counter psychoactive drug, prescription psychoactive drug or drug that would have major interaction with drugs to be tested. 6. History of severe reaction to Narcan challenge, which may have been given as part of admission into the Methadone Maintenance Program or to reverse overdose. 7. Liver function tests greater than 3 times normal, BUN and Creatinine outside normal range, or thyroid function tests outside normal range. 8. EKG abnormalities including but not limited to: bradycardia (<60 bpm); prolonged with QTc interval (>420 msec); Wolff-Parkinson White syndrome; wide complex tachycardia; 2nd degree, Mobitz type II heart block; 3rd degree heart block; left or right bundle branch block.

Locations and Contacts

University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States
Additional Information

Starting date: September 2006
Last updated: March 10, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017